Anti-malarial Drugs Market, By Drug Class (Aminoquinolines, Quinoline-methanol (4-quinolinemethanols), Cinchona Alkaloids, Biguanides, Sulfonamides and Sulfones, and Others), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Jun 2023

Code : CMI3726

Pages :162

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Global Anti-malarial Drugs Market – Driver

Increasing regional government funds and increasing prevalence of malaria

Increasing incidence of malaria is expected to boost growth of the global anti-malarial drugs market over the forecast period. Increasing regional government funds for the development and research can also propel the growth over the forecast period. For instance, on April 24 2023, the U.S. and Mali worked together to provide malaria services that saved lives and supported communities. Investments in malaria prevention and treatment tools, along with the training and equipping of health workers, advanced Mali’s progress against the disease while strengthening the country’s health system. The U.S. President’s Malaria Initiative (PMI) has partnered with Mali to fight malaria since, contributing US$ 364 million to date and US$ 25 million in FY 2022. PMI’s Annual Report, released, showcases how PMI is working with partner countries, such as Mali to help make sure all those at risk from malaria are protected and to support local communities to shape and lead activities to end malaria faster.

Restraints & Challenges:

Severe side effects associated with the drugs

Global Anti-malarial Drugs Market: Restraint

Severe side effects associated with the drugs

Most of the anti-malaria drugs are associated with severe side effects, such as heart rhythm problems and other safety issues, including blood and lymph system disorders, kidney injuries, and liver problems and failure, which is expected to decrease demand for these drugs. For instance, in July 2020, the U.S. FDA warned against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. The U.S. FDA is aware of reports of serious heart rhythm problems in patients with COVID-19 treated with hydroxychloroquine or chloroquine, often in combination with azithromycin and other QT prolonging medicines.